Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04900454 | Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 | PHASE1 | COMPLETED | 12 | — | — | Jul 1, 2021 | Jun 1, 2022 | Apr 7, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| DVX201 | BIOLOGICAL | Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells |